Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection

ClinicalTrials.gov ID: NCT01482767

Public ClinicalTrials.gov record NCT01482767. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Phase III, Open-Label Study of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Hepatitis C virus (HCV) infection is a leading cause of death and illness in people with HIV-1. At the time the study was designed, the standard treatment for people with HIV-1 and HCV coinfection included two drugs: pegylated-interferon alfa 2b (PEG-IFN) and ribavirin (RBV). The purpose of this study was to evaluate the effectiveness of giving boceprevir (BOC) together with standard treatment in treating HCV infection in people with HIV-1 and HCV coinfection.

Study identification

NCT ID
NCT01482767
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
262 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 2012 (Type not available)
Primary completion
Apr 2015 (Actual)
Completion
Apr 2015 (Actual)
Last update posted
Nov 4, 2021

2012 – 2015

United States locations

U.S. sites
42
U.S. states
20
U.S. cities
33
Facility City State ZIP Site status
Alabama CRS Birmingham Alabama 35294 —
University of Southern California CRS Los Angeles California 90033-1079 —
UCLA CARE Center CRS Los Angeles California 90035 —
Stanford AIDS Clinical Trials Unit CRS Palo Alto California 94304-5350 —
UCSD Antiviral Research Center CRS San Diego California 92103 —
Ucsf Hiv/Aids Crs San Francisco California 94110 —
Harbor-UCLA CRS Torrance California 90502 —
University of Colorado Hospital CRS Aurora Colorado 80045 —
Denver Public Health CRS Denver Colorado 80204 —
Georgetown University CRS (GU CRS) Washington D.C. District of Columbia 20007 —
The Ponce de Leon Center CRS Atlanta Georgia 30308-2012 —
Northwestern University CRS Chicago Illinois 60611 —
Rush University CRS Chicago Illinois 60612 —
IHV Baltimore Treatment CRS Baltimore Maryland 21201 —
Johns Hopkins University CRS Baltimore Maryland 21205 —
Massachusetts General Hospital CRS (MGH CRS) Boston Massachusetts 02114 —
Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS Boston Massachusetts 02115 —
Bmc Actg Crs Boston Massachusetts 02118 —
Wayne State Univ. CRS Detroit Michigan 48201 —
Henry Ford Hosp. CRS Detroit Michigan 48202 —
Washington University Therapeutics (WT) CRS St Louis Missouri 63110-1010 —
Cooper Univ. Hosp. CRS Camden New Jersey 08103 —
New Jersey Medical School Clinical Research Center CRS Newark New Jersey 07103 —
Weill Cornell Chelsea CRS New York New York 10011 —
Columbia P&S CRS New York New York 10032-3732 —
Weill Cornell Uptown CRS New York New York 10065 —
University of Rochester Adult HIV Therapeutic Strategies Network CRS Rochester New York 14642 —
Bronx-Lebanon Hosp. Ctr. CRS The Bronx New York 10457 —
Chapel Hill CRS Chapel Hill North Carolina 27599 —
Duke Univ. Med. Ctr. Adult CRS Durham North Carolina 27710 —
Cincinnati Clinical Research Site Cincinnati Ohio 45219 —
Case Clinical Research Site Cleveland Ohio 44106 —
MetroHealth CRS Cleveland Ohio 44109 —
Ohio State University CRS Columbus Ohio 43210 —
Penn Therapeutics, CRS Philadelphia Pennsylvania 19104 —
University of Pittsburgh CRS Pittsburgh Pennsylvania 15213 —
The Miriam Hospital Clinical Research Site (TMH CRS) CRS Providence Rhode Island 02906 —
Vanderbilt Therapeutics (VT) CRS Nashville Tennessee 37204 —
Trinity Health and Wellness Center CRS Dallas Texas 75208 —
Houston AIDS Research Team CRS Houston Texas 77030 —
Virginia Commonwealth University CRS Richmond Virginia 23298 —
University of Washington AIDS CRS Seattle Washington 98104-9929 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01482767, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 4, 2021 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01482767 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →